MindCure signs LOI to make a strategic investment in ATMA, a psychedelics-assisted therapy center in Calgary, Alberta.
MindCure signs LOI to make a strategic investment in ATMA, a psychedelics-assisted therapy center in Calgary, Alberta.
ATAI Life Sciences and MindMed Inc have the deepest psychedelics operations in this sector. Which is the better opportunity?
KCSA Communications hosts an investment conference featuring Rick Doblin (MAPS) as a keynote speaker.
MindMed closes on a CAD$92.1 million financing from what was originally a $50 million offering. Total cash on hand increases to US$144.4 million.
The ATAI Life Sciences IPO could come as soon as the end of January. What does this mean for psychedelic stock investors?
Numinus announces a product development agreement with Optimi Health Corp.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now